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Abstract Objective: To investigate the frequency of use
and misuse of sumatriptan, and to explore the char-
acteristics of patients reporting overuse.
Setting: A postmarketing cohort study on adverse 
reactions to sumatriptan, performed with the assis-
tance of drug-dispensing general practitioners in the
Netherlands.
Methods: Questionnaires were sent to patients on suma-
triptan of drug-dispensing general practitioners in the
Netherlands. Use of sumatriptan was classified into five
groups: < 1, 1–10, 11–20 and 21–30 times per month
and a group of patients who reported daily use of
sumatriptan more than 10 times per week. Patients in
the latter group were regarded as “overusers”.
Results: The request to the 1720 patients yielded a
response rate of 1202 (70%). Of 952 (79%) of these
patients, details of their sumatriptan intake were avail-
able. Most patients (718, 75%) took sumatriptan 1–10
times each month. However, 36 patients (4%, 95% CI
2.8–5.2%) took sumatriptan daily or more than 10
times each week. The group with the highest intake
consisted mainly of males, and many patients who
reported a poor efficacy of sumatriptan. Age was not
related to use of sumatriptan.
Conclusions: A small group of patients (4%) used suma-
triptan too often. A high intake was associated with
both male gender and a reported poor efficacy of suma-
triptan, but not with age, reported adverse reactions,
or headache attributed to sumatriptan. It is important
to explain to patients that sumatriptan is only for the
treatment of acute attacks, and not for prophylactic
use. Drug consumption patterns have to be evaluated,
in particular in patients who report low efficacy of
sumatriptan.
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The serotonin-1 agonist sumatriptan is a relatively new
drug used in the treatment of acute attacks of migraine
and cluster headache [1]. Adverse drug reactions attrib-
uted to sumatriptan in the postmarketing period
include acute myocardial infarction [2, 3], depression
[4] and skin reactions [5]. A characteristic feature is the
recurrence of headache within 24 h after administra-
tion of sumatriptan [6]. Since marketing of the drug,
several patients have been observed who developed an
increase in the frequency of migraine attacks with con-
sequent dependence and misuse, after use of suma-
triptan [7–9]. Preliminary results of a postmarketing
study based on pharmacy records have also shown mis-
use of sumatriptan by approximately 1% of consumers
[10]. We investigated the frequency of use and misuse
of sumatriptan in a postmarketing cohort study, and
explored the characteristics of patients reporting
overuse.
Methods and data analysis
In May 1991, sumatriptan was registered in the Netherlands for 
the treatment of acute attacks of migraine and cluster headache. In
July 1992, we conducted an enquiry and all 687 drug-dispensing
general practitioners (GPs) in the Netherlands were contacted, to
obtain the date of birth and gender of every person to whom 
they had dispensed sumatriptan since marketing. Subsequently, 
they were asked to send a questionnaire to the patients who had
used sumatriptan, to be completed at home. The questionnaires
were sent via the GP in prestamped envelopes with a standard
letter from our centre. In the questionnaire, the patients were asked
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whether they had indeed used sumatriptan and, if so, how often
sumatriptan was used, what the efficacy of sumatriptan was and
whether they had observed any adverse reaction after use of suma-
triptan. No adverse reactions were mentioned by name in the ques-
tionnaire. Some details of the study have been published previously
[11, 12].
Use of sumatriptan was classified into five groups: < 1, 
1–10, 11–20 and 21–30 times per month, and a fifth group of
patients who reported daily sumatriptan use or use more than 
10 times each week. Patients in the latter group were regarded as
“overusers”.
Differences between group means were tested by Student’s t-test.
A chi-square test was used to assess differences between propor-
tions, with use of Fisher’s exact test if there was an expected 
cell value of less than 5. All calculated P values are two-tailed.
Statistical significance was defined as a two-sided P-value of 
less than 0.05. Relative risks (RR) were calculated with 95%
confidence intervals (95% CI).
Results
Of the 589 Dutch GPs (86%) who participated in this
study, 474 had dispensed sumatriptan on at least one
occasion to a total of 1727 patients (24% males, 76%
females). During the study period, seven patients were
lost to follow-up, all from change of address. Of the
1720 remaining patients, 1202 (70%) returned the ques-
tionnaire. With 952 (79%) of these patients full details
of their sumatriptan intake were available.
Basic characteristics of the study population are
summarized in Table 1. A total of 34 patients (4%)
reported (rebound) headache due to use of sumatrip-
tan, 6 males and 28 females (gender distribution not
significantly different from the other patients). In 
Fig. 1 the consumption of sumatriptan is depicted.
Most patients (718, 75%) consumed sumatriptan 1–10
times each month. Thirty-six patients (4%, 95% CI
2.8–5.2%) used sumatriptan daily or more than 
10 times each week, and were regarded as “overusers”,
of whom 17 patients used sumatriptan once every day,
14 patients took sumatriptan 2 times each day, 3
patients three times each day, and 2 patients reported
that they used sumatriptan more than 10 times each
week (not specified per day). Of the 36 patients, 13
(36%) were males, which was more than in the patients
who used sumatriptan less than 10 times per month
(192 males, relative risk 1.9, 95% CI 1.0–3.7). There
were no differences in age, duration of headache com-
plaints or  route of administration between the five
intake groups. Of the 36 patients who took sumatrip-
tan daily or more than 10 times each week, 6 patients
reported the efficacy of sumatriptan as poor, compared
to 49 patients of the 916 patients who used sumatrip-
tan less than 30 times each month (RR = 3.3 95% CI
1.4–7.5). One or more adverse reactions were reported
by 18 patients (50%) of the overusers, compared to 511
patients (56%) of the others (P = 0.5). Headache as an
adverse reaction to sumatriptan was reported by 1
“overuser” (2.8%), compared to 33 patients in the other
groups (3.6%; not significantly different).
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Table 1 Basic characteristics of 952 patients with information on
sumatriptan consumption (SD standard deviation)
Characteristic Number or mean
Age (years) 44 (SD: 11)
Males 224 (24%)
Reported efficacy of sumatriptan
– Good 729 (77%)
– Moderate 77 (8%)
– Poor 55 (6%)
– Not reported 91 (9%)
Route of administration
– Oral 318 (33%)
– Subcutaneous 458 (48%)
– Both routes 82 (9%)
– Missing 94 (10
Average duration of
headache complaints (years) 21 (SD: 13)
Any adverse reaction 529 (56%)
Headache after sumatriptan 34 (4%)
Fig. 1 Consumption of
sumatriptan in 952 patients of
drug-dispensing general
practitioners. Consumption
was classified into five groups:
< 1, 1–10, 11–20 and 21–30
times per month and a group
of patients who reported daily
use sumatriptan or use more
than 10 times each week
Discussion
We found that a small proportion (4%) of the con-
sumers used sumatriptan daily or more than 10 times
each week. Since sumatriptan is a drug for acute attacks
of migraine or cluster headache, and not for prophy-
lactic use, we regarded this group as “overusers”. It has
previously been recommended that patients with
headaches should never take analgesics every day, and
that ergotamine should not be taken more than 10 times
a month [13]. Overuse in our study was significantly
more frequently observed in males, and in patients who
reported the efficacy of sumatriptan as poor.
Analyses of medication consumption based on
dispensing or reimbursement data have two major lim-
itations: (1) no information is available on non-com-
pliance and (2) no information is available on drugs
which are bought “over the counter”. Furthermore,
these pharmacy record based studies do not provide
direct information on efficacy, clinical events or adverse
drug reactions observed by consumers. In our post-
marketing study we used information of drug use
obtained directly from consumers. Because of strict pri-
vacy rules in the Netherlands, we were not able to val-
idate these data by evaluating the records of the drug-
dispensing general practitioners. We think, however,
that these data give good insight into the consumption
of sumatriptan in these patients, although negative
misclassification may exist.
Several explanations for overuse may be considered.
The most important reason for more frequent use of
sumatriptan is possibly a higher attack rate of migraine
or cluster headache, but information on attack rates
was not available in our study. However, it was demon-
strated in our study that an observed low efficacy of
sumatriptan accompanied more frequent overuse.
Previously, headache recurrence after sumatriptan use
was reported [14–16]. It has been suggested that the
rebound headache may be the underlying mechanism
of over-use of sumatriptan [10, 15]. However, the
(rebound) headache was not associated with overuse in
our study. Another explanation, more compatible with
our data, is that some patients use sumatriptan in too
low a dose or that in some patients the activity of suma-
triptan is too short.
In conclusion, we found that 4% of patients con-
suming sumatriptan used this drug daily or more than
10 times per week. Overuse was associated with a
reported poor efficacy of sumatriptan and with male
gender, but not with (rebound) headache after suma-
triptan use. Drug consumption patterns of sumatrip-
tan have to be evaluated in all patients, but in particular
in patients who report low efficacy of sumatriptan.
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